Business Context and Reporting Period
This Form 8-K is a current report filed by Genesis Biopharma, Inc. (not IOVANCE BIOTHERAPEUTICS, INC.) on March 16, 2011. The filing discloses a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Monthly Board Retainer: $3,000
- Stock Option Grant: 250,000 shares
- Exercise Price: $1.25 per share
- Option Term: 10 years
Material Changes
The material change reported is the addition of Dr. William Andrews to the Board of Directors. Dr. Andrews brings experience as the founder and CEO of Sierra Services, LLC, and previously held molecular biology director roles at Geron Corporation and Codon Corporation/Berlex Biosciences.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, risk factors, or discussion of contingencies. It is strictly a disclosure of the director appointment and associated compensatory arrangements.
Investor Verification Checklist
- Verify the correct issuer name is Genesis Biopharma, Inc., as the request metadata incorrectly listed IOVANCE BIOTHERAPEUTICS, INC.
- Confirm the vesting schedule for the 250,000 stock options (vests on the anniversary of appointment).
- Review the Company's 2010 Equity Compensation Plan to understand the total pool of shares available for issuance.
- Check subsequent filings for any changes to the Board composition or Dr. Andrews' tenure.